CHEHealthcare · Medical Care FacilitiesThe 4 Wall Street analysts covering Chemed Corp. hold a median 12-month price target of $549 — +10.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 23 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Chemed Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (91): Analysts have, on balance, been raising their forecasts.
Growth (51): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (19): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CHE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +10.8% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 July 2026 | Oppenheimer | Maintains | Outperform | $500 → $590 |
| 30 July 2026 | RBC Capital | Maintains | Sector Perform | $436 → $548 |
| 9 July 2026 | B of A Securities | Maintains | Neutral | $450 → $510 |
| 9 July 2026 | B of A Securities | Maintains | Neutral | — |
| 27 Apr 2026 | RBC Capital | Maintains | Sector Perform | — |
| 27 Feb 2026 | Oppenheimer | Maintains | Outperform | — |
| 27 Feb 2026 | RBC Capital | Downgrade | Sector Perform | — |
| 22 Jan 2026 | Jefferies | Downgrade | Hold | — |
| 10 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 10 Sept 2025 | B of A Securities | Maintains | Buy | — |
| 2 Sept 2025 | Jefferies | Upgrade | Buy | — |
| 31 July 2025 | Oppenheimer | Maintains | Outperform | — |
| 31 July 2025 | RBC Capital | Maintains | Outperform | — |
| 25 July 2025 | Jefferies | Initiates | Hold | — |
| 30 June 2025 | B of A Securities | Maintains | Buy | — |
| 30 June 2025 | RBC Capital | Maintains | Outperform | — |
| 28 Apr 2025 | RBC Capital | Maintains | Outperform | — |
| 14 Mar 2025 | RBC Capital | Maintains | Outperform | — |
| 5 Nov 2024 | RBC Capital | Maintains | Outperform | — |
| 21 May 2024 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CHE appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Sept 2026, Chemed Corp. returned +9.0% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 30% of US stocks
Cheaper than 46% of US stocks
Cheaper than 12% of US stocks
Cheaper than 20% of US stocks
Higher than 49% of US stocks
Higher than 65% of US stocks
Higher than 38% of US stocks
Higher than 70% of US stocks
Higher than 71% of US stocks
Higher than 86% of US stocks
Higher than 96% of US stocks
Higher than 11% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Chemed Corp. has a market value of $6.5B and an enterprise value of $6.7B.
Revenue in the twelve months to 31 Mar 2026: $2.5B. The latest quarter grew 8.8% year on year.
Net income over the same four quarters: $259.8M, a 10.2% net margin.
Diluted earnings per share, trailing twelve months: $18.35.
Free cash flow in the twelve months to 31 Mar 2026: $377.1M, after $50.5M of capital spending.
Chemed Corp. spent $588.3M on share buybacks and $32.5M on dividends in the twelve months to 31 Mar 2026.
Trailing P/E: 25.0×; forward P/E: 18.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.56%, paying out 12% of earnings.
Chemed Corp. employs 15,811 people — $161K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Chemed Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation, announced it has acquired the largest independent Roto-Rooter franchise, which serves approximately 11 million people, for $60.6 million.
Why it matters — The acquisition expands Roto-Rooter's corporate-owned service territory and could strengthen Chemed's market presence in a major population area.
Chemed Corporation presented at the 2026 Jefferies Healthcare Services and Technology Conference, with the event covered in a Seeking Alpha transcript. The presentation transcript documents Chemed's remarks at the conference.
Why it matters — CHE watchers would care because conference presentations can offer insight into the company's current positioning and outlook within the healthcare services sector.
Chemed Corporation announced it will present at the Jefferies 2026 Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at approximately 10:55 a.m. The presentation will take place in Cincinnati per the announcement.
Why it matters — The presentation offers CHE watchers an opportunity to hear management discuss the company's business at a major healthcare industry conference.
Chemed executive Spencer Lee sold 1,000 shares on Aug. 21 in a transaction valued at approximately $541,040. The sale reduced his direct equity holdings by 7%.
Why it matters — A corporate insider's share sale is noteworthy to CHE watchers as it reflects a change in the executive's direct ownership stake in the company.
Scott+Scott Attorneys at Law LLP announced it is investigating whether Chemed Corporation's officers and directors breached their fiduciary duties to the company and whether Chemed and its shareholders have suffered damages as a result. The probe, led by attorney Joseph A. Pettigrew, follows an August 13, 2026 report released by The Capital Forum.
Why it matters — A law firm has launched an investigation into possible breaches of fiduciary duty by Chemed's leadership, which could signal governance concerns for shareholders.
The 4 Wall Street analysts covering Chemed Corp. have a median 12-month price target of $549, with estimates ranging from $520 to $590. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Chemed Corp., 1 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Chemed Corp. 86 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Sept 2026, Chemed Corp. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (91 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +10.8% from the last close, and Ticker Nerd's factor model ranks Chemed Corp. 86 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Chemed Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CHE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $520 to $590 over the next 12 months.
Chemed Corp. returned +9.0% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Chemed Corp. is a diversified holding company focused on healthcare and essential home services.
The most recent item we track (GlobeNewsWire, 16 Sept 2026): "Roto-Rooter Buys Largest Franchisee Territory". Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation, announced it has acquired the largest independent Roto-Rooter franchise, which serves approximately 11 million people, for $60.6 million.
Chemed Corp. is a diversified holding company focused on healthcare and essential home services. Its operations are organized around two core segments: VITAS, which provides hospice and palliative care through a multidisciplinary network of clinicians and caregivers, and Roto-Rooter, which delivers plumbing, drain cleaning, excavation, and water restoration services to residential and commercial customers. Chemed Corp. serves patients, families, homeowners, businesses, and property managers across the United States, combining end-of-life care services with maintenance and emergency repair solutions. The company’s business model centers on operating specialized service brands with distinct customer needs and market dynamics, giving it a unique position in both healthcare services and home repair markets.
CEO Mr. Kevin J. McNamara · 15,811 employees · United States · https://www.chemed.com
